An annual screening for breast cancer using a combination of MRI and mammography could be an effective program for high-risk women, particularly those who are known BRCA mutation carriers.
In this overview, we will review recent developments in the management of breast cancer brain metastases and current prospective trials of systemic therapies specifically for patients with breast cancer brain metastases, with a focus on novel pathway-specific therapies.
Prevention of CNS seeding early in the metastatic disease course using drugs with both intra- and extracranial activity will be crucial to improving outcomes in patients with breast cancer brain metastases.
Brain metastases arising from breast cancer constitute a clinically unmet need and a situation that portends a poor prognosis with few therapeutic options.
For many women, the prospect of tumors growing in their brain that may eventually impact their ability to communicate, interact, and remember is terrifying.
Dr. Pagani, who presented data on the joint analysis of the IBCSG TEXT and SOFT trials at the 2014 ASCO Annual Meeting, discusses how breast cancer patients in these trials responded to different methods of ovarian suppression.
Dr. Pagani, who presented data on the joint analysis of the IBCSG TEXT and SOFT trials at the 2014 ASCO Annual Meeting, discusses how breast cancer patients in these trials responded to different methods of ovarian suppression.
More than 90% of women about to undergo a mammography were unable to accurately quantify their risk for breast cancer, either over- or underestimating their risk, according to the results of a large-scale survey presented at the ASCO Breast Cancer Symposium 2013.
Expert radiologists were able to screen magnetic resonance images and rule out breast cancer diagnosis with a negative predictive value of about 99% using an abridged breast MRI protocol in a single-center study presented Saturday at the ASCO Breast Cancer Symposium 2013.
As part of our coverage of the 2014 ASCO Annual Meeting, we discuss treatment strategies for breast cancer patients who harbor either the BRCA1 or BRCA2 mutation.
In this Circling Back feature, authors of the review article “Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Long Enough?” discuss some of the especially interesting points made in the commentaries.
A recent prospective trial showed sentinel lymph node surgery has a clinically significant high false negative rate in breast cancer patients with node-positive disease receiving neoadjuvant chemotherapy. In this interview we discuss surgical techniques that detect breast cancer in lymph nodes.
As part of our coverage for the ASCO Breast Cancer Symposium 2013, we spoke with Dr. Susan K. Boolbol, chief of the division of breast surgery at the Appel-Venet Comprehensive Breast Service at Beth Israel Medical Center in New York City, who is chairing a general session panel discussion on the overdiagnosis of breast cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.
![Subscribe to Breast Cancer on [sitename]](http://www.cancernetwork.com/misc/feed.png){kind=small}
